Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria.
about
H1-antihistamines for chronic spontaneous urticariaGuideline of Chronic Urticaria BeyondPosition statement for the use of omalizumab in the management of chronic spontaneous urticaria in Indian patientsAdvances in Understanding and Managing Chronic UrticariaChronic spontaneous urticaria: latest developments in aetiology, diagnosis and therapyProfile of omalizumab in the treatment of chronic spontaneous urticariaImmunoglobulin E in irritable bowel syndrome: another target for treatment? A case report and literature reviewManagement of urticaria: not too complicated, not too simpleChronic urticaria in adults: state-of-the-art in the new millenniumApproaches to the diagnosis and management of chronic urticaria in childrenWhy we scratch an itch: the molecules, cells and circuits of itchTreatment of Refractory Chronic UrticariaTwo potential therapeutic antibodies bind to a peptide segment of membrane-bound IgE in different conformationsPersonalized Medicine in AllergyBiologics in asthma--the next step toward personalized treatmentTemporal Regulation by Innate Type 2 Cytokines in Food Allergies.Questions and answers in chronic urticaria: where do we stand and where do we go?Risk and safety requirements for diagnostic and therapeutic procedures in allergology: World Allergy Organization StatementClinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FcεRI-positive cells in the skin.Increased cis-to-trans urocanic acid ratio in the skin of chronic spontaneous urticaria patients.Accelerated dissociation of IgE-FcεRI complexes by disruptive inhibitors actively desensitizes allergic effector cells.A disease marker for aspirin-induced chronic urticaria.Double-blind placebo-controlled trial of dapsone in antihistamine refractory chronic idiopathic urticaria.Outcomes of off-label drug uses in hospitals: a multicentric prospective studyOmalizumab in children.Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study.Omalizumab vs. placebo in the management of chronic idiopathic urticaria: a systematic review.The care pathway for children with urticaria, angioedema, mastocytosisSuccessful and Safe Treatment of Chronic Spontaneous Urticaria with Omalizumab in a Woman during Two Consecutive Pregnancies.Omalizumab, an anti-immunoglobulin E antibody: state of the art.Insights and advances in chronic urticaria: a Canadian perspective.A pilot study of omalizumab in eosinophilic esophagitisSuppression of basophil FcɛRI activation by serum from active chronic idiopathic/spontaneous urticaria (CIU/CSU) subjectsChronic urticaria merits serum vitamin D evaluation and supplementation; a randomized case control study.Structural and Physical Basis for Anti-IgE Therapy.Retrospective case note review of chronic spontaneous urticaria outcomes and adverse effects in patients treated with omalizumab or ciclosporin in UK secondary care.Resource use and costs in an insured population of patients with chronic idiopathic/spontaneous urticariaOmalizumab for Urticarial Vasculitis: Case Report and Review of the Literature.Comparison of Efficacy, Safety and Cost-effectiveness of Rupatadine and Olopatadine in Patients of Chronic Spontaneous Urticaria: A Randomized, Double-blind, Comparative, Parallel Group TrialAssessing Changes in Chronic Spontaneous/Idiopathic Urticaria: Comparisons of Patient-Reported Outcomes Using Latent Growth Modeling.
P2860
Q24187983-2FC24BCF-EF79-4F1E-81E9-997010364C8BQ26743369-6554E521-266D-460E-B57A-7563C2D07BEFQ26767180-3120BA88-FC6F-4B3B-B261-6AF61AF5B17FQ26767461-2892480E-A708-43D9-8639-649B907A39D4Q26777088-807F0373-ADF9-400D-AED8-99DF182F3610Q26783158-E72A4DAD-2AAA-4A3F-913F-D1CDA98B05DFQ26795564-B518EDB5-421A-4BE9-B85A-90D931E6A16BQ26828373-A0B60589-5180-424C-B87E-9157E0276330Q26849258-1582746A-70BF-4F04-8886-206E66CA7E4CQ26852686-882001D4-247D-42AA-AFC0-2D4BB348D075Q26865093-5F9A1087-872B-4487-BF86-CBC22CC796DAQ26865314-D1C68A99-2BEE-4F5A-AC03-A9D277F8831AQ27688964-11086E1C-3459-4050-8397-1D3BF0DD2BB1Q28073074-DC4FCC79-6496-4BBA-B9B6-F3BA33D8B01EQ28085614-4532411A-D148-4745-95FF-8E22CF69D186Q30244169-29F23AB9-9C52-4A21-8658-39CA2B3692E9Q30249703-B6E610B1-58A4-41E6-BCC4-671645398BD8Q30371972-FE88A3EF-C1A5-4378-AC74-DA1E49EDD591Q33588223-1A4214FC-6619-4891-ACF9-CFA137E0105DQ33683786-3F2F3B72-821C-4C5F-BAFB-7603BA884702Q33850604-9B6DDCD0-D49F-45E6-92FB-1D99E45D4B4FQ34072462-1ED33C95-72D7-4DA7-BADB-87E88481EBFCQ34194291-9D3E0E69-F91D-44EC-B100-C59EDBA58096Q34347118-4BEAED78-315E-4A41-B0EA-BBD62FF7CC10Q34604574-8441B41C-3925-449E-BF2D-0891E8219D97Q34727734-C89D8751-D67A-430F-B5D8-B9FC11BADBEAQ34794295-1E64631C-EA1F-4FCD-864E-D9E10259639AQ35036770-8532BC3C-7F9C-4F56-BFE8-8CA3E01477B7Q35078702-119E6D09-CB37-4F68-8713-CBE3D1BBC204Q35095218-BA2A7601-9F95-40BE-ABFA-0CEB40813D94Q35108534-15E8AF96-60EC-4231-85F7-324635850176Q35195626-93BE371D-EA4A-440D-A67A-1B3DA5D276EAQ35478921-C34CEC90-31F7-4A8C-A753-1E13CE92DC55Q35682559-BDFA5C85-1062-4FC5-9686-F44651953FD9Q35783662-125EA87C-6357-483A-A16D-B4837906C35FQ35865960-B3599098-AF94-4463-AC3F-225D2DEBFF34Q35930834-F3038F70-F5DF-45E8-A3DF-9E2BC11DBF3FQ36082959-A40341EC-2417-431C-8359-4141545204D5Q36607273-A63EA533-8A00-44B0-9D62-9D8996129BFCQ36626205-B396B123-224C-4EF6-B517-254EA41CC928
P2860
Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria.
description
2013 nî lūn-bûn
@nan
2013 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria.
@ast
Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria.
@en
Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria.
@nl
type
label
Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria.
@ast
Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria.
@en
Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria.
@nl
prefLabel
Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria.
@ast
Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria.
@en
Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria.
@nl
P2093
P356
P1476
Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria
@en
P2093
Allen Kaplan
Ana Gimenéz-Arnau
Clive Grattan
Hsin-Ju Hsieh
Karin Rosén
Marcus Maurer
Ramona Doyle
Sarbjit Saini
Sunil Agarwal
Thomas Casale
P304
P356
10.1056/NEJMOA1215372
P407
P577
2013-02-24T00:00:00Z